Mucormycosis is one of an array of ferocious fungal diseases that have attacked COVID patients, including a lethal yeast called Candida auris and a spate of infections with Aspergillus fungi that have earned the acronym CAPA (for COVID-associated pulmonary aspergillosis).
These fungal infections arise after a COVID diagnosis, which seems to be a clue. A standard component of treatment for severe cases of COVID is high doses of corticosteroids,
anti-inflammatory drugs that damp down the immune system’s overreaction to infection. Steroids save lives, but
they simultaneously make a patient more vulnerable to attack by whatever bacteria or fungi are already in their body or hanging around their environment.
“Fungal spores are everywhere, but we are pretty efficient at clearing them from our lungs,” says Arturo Casadevall, a physician and molecular microbiologist at the Johns Hopkins Bloomberg School of Public Health. “But COVID damages the lung. So then you have a double whammy: reduced capacity to naturally clear the spores and reduced immune response as a result of steroids.”
That collision of factors is complicated by something else. Years before COVID appeared, researchers in Australia and Europe, as well as India, all reported that mucormycosis seemed particularly ferocious in patients with
uncontrolled diabetes. That is setting Indian COVID patients up for disaster. “Even in rural areas,
every eighth adult aged 30 and beyond is diabetic,” Kalantri says. “Most have suboptimal control of sugar. When these patients test COVID-positive, they often are prescribed high-dose steroids, often in the first week. Irrational and unscientific treatment of COVID is extremely common.”
...
https://www.scientificamerican.com/...k-fungus-is-ravaging-covid-patients-in-india/